We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$84M
AUM Growth
-$31.4M
Cap. Flow
-$24.4M
Cap. Flow %
-29.07%
Top 10 Hldgs %
66.01%
Holding
53
New
14
Increased
7
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$5.79M
2
PFE icon
Pfizer
PFE
+$5.13M
3
TVTX icon
Travere Therapeutics
TVTX
+$4.82M
4
LEGN icon
Legend Biotech
LEGN
+$3.26M
5
CAPR icon
Capricor Therapeutics
CAPR
+$2.58M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$8.55M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$6.66M
3
GPCR icon
Structure Therapeutics
GPCR
+$5.88M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$5.84M
5
ZLAB icon
Zai Lab
ZLAB
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
1
Zai Lab
ZLAB
$2.28B
$10.7M 12.68%
294,947
-108,683
-27% -$3.34M
BBIO icon
2
BridgeBio Pharma
BBIO
$15.9B
$6.36M 7.56%
183,922
-78,219
-30% -$2.64M
VRNA
3
DELISTED
Verona Pharma
VRNA
$6.15M 7.31%
+96,821
New +$5.79M
LEGN icon
4
Legend Biotech
LEGN
$4.31B
$5.44M 6.48%
160,442
+90,848
+131% +$3.26M
PFE icon
5
Pfizer
PFE
$143B
$4.97M 5.91%
+196,164
New +$5.13M
URGN icon
6
UroGen Pharma
URGN
$1.96B
$4.69M 5.57%
423,632
+122,426
+41% +$1.31M
COGT icon
7
Cogent Biosciences
COGT
$6.68B
$4.64M 5.52%
774,721
-136,144
-15% -$1.07M
ORIC icon
8
Oric Pharmaceuticals
ORIC
$1.11B
$4.57M 5.44%
819,194
-761,551
-48% -$6.66M
TVTX icon
9
Travere Therapeutics
TVTX
$5.27B
$4.26M 5.06%
+237,487
New +$4.82M
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
$3.75M 4.46%
1,357,153
-663,409
-33% -$2.71M
CYTK icon
11
Cytokinetics
CYTK
$10.9B
$2.93M 3.49%
72,992
-56,397
-44% -$2.59M
SVRA icon
12
Savara
SVRA
$1.13B
$2.68M 3.18%
966,203
+457,865
+90% +$1.26M
SMMT icon
13
Summit Therapeutics
SMMT
$10.7B
$2.55M 3.03%
132,019
-32,545
-20% -$653K
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
$2.39M 2.85%
+54,216
New +$2.5M
CAPR icon
15
Capricor Therapeutics
CAPR
$1.13B
$2.29M 2.72%
241,192
+185,963
+337% +$2.58M
VSTM icon
16
Verastem
VSTM
$530M
$2.03M 2.41%
336,363
+126,474
+60% +$773K
TARA icon
17
Protara Therapeutics
TARA
$230M
$1.53M 1.82%
360,000
– –
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$8.88B
$1.46M 1.74%
+43,613
New +$1.63M
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
$1.38M 1.64%
+19,332
New +$941K
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12.8B
$1.26M 1.5%
3,815
+2,686
+238% +$883K
MLTX icon
21
MoonLake Immunotherapeutics
MLTX
$1.64B
$1.26M 1.49%
+32,145
New +$1.39M
TSHA icon
22
Taysha Gene Therapies
TSHA
$1.71B
$1.05M 1.25%
+755,599
New +$1.26M
TECX
23
Tectonic Therapeutic
TECX
$615M
$899K 1.07%
+50,746
New +$1.65M
ZBIO
24
Zenas BioPharma
ZBIO
$1.86B
$882K 1.05%
111,605
– –
ETNB
25
DELISTED
89bio
ETNB
$794K 0.94%
109,156
-23,826
-18% -$208K
1
2 3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Superstring Capital Management held 53 positions worth $84M, down 27% from $115M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Superstring Capital Management withdrew a net $24.4M in Q1 2025, closing 19 positions and reducing 9 holdings. Its most notable exit was NovoCure, an estimated $8.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Verona Pharma worth $6.15M.

  • Superstring Capital Management's largest Q1 2025 buy was Verona Pharma: 96,821 shares worth $6.15M.
  • Superstring Capital Management added most to Legend Biotech in Q1 2025, an estimated $3.26M increase.
  • Superstring Capital Management's biggest Q1 2025 reduction was Oric Pharmaceuticals, cutting an estimated $6.66M.
  • Superstring Capital Management fully exited NovoCure in Q1 2025, selling an estimated $8.55M.
  • Superstring Capital Management's ten largest holdings make up 66% of its $84M portfolio in Q1 2025.
  • Superstring Capital Management opened 14 new positions and closed 19 in Q1 2025.
  • Superstring Capital Management's portfolio value fell 27% quarter-over-quarter to $84M.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.